Armata Pharmaceuticals, Inc. 8K

Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 bacteriophage therapy for complicated Staphylococcus aureus bacteremia, potentially accelerating its development and review.

Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA, based on compelling Phase 1b/2a data from the diSArm study showing improved and durable clinical cure rates when added to best available antibiotic therapy. This new status, which adds to the candidate’s existing Fast Track and Qualified Infectious Disease Product designations, is intended to expedite development and review through enhanced FDA collaboration and may accelerate AP-SA02’s path to a planned Phase 3 superiority trial anticipated to begin in the second half of 2026 and potential future approval.

Filing Facts

CIK

921114

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-107253

Alert Tier

6